Michelle T. Long MD, MSc

Associate Professor, Preventive Medicine & Epidemiology

Associate Professor, Gastroenterology

85 E. Concord St | (617) 638-8392
Michelle Long
Sections

Preventive Medicine & Epidemiology

Gastroenterology

Centers

Framingham Heart Study

Boston Nutrition Obesity Research Center

Evans Center for Interdisciplinary Biomedical Research

Biography

Michelle T. Long, MD, MSc is a physician-scientist with an expertise in Nonalcoholic fatty liver disease (NAFLD), and an Associate Professor of Medicine at Boston University. She completed her clinical training at Massachusetts General Hospital and Boston Medical Center. Dr. Long is the Director of the NAFLD Research Center and the Director of Clinical Research for the Section of Gastroenterology and Hepatology. Her clinical and research interests center on the relationship between NAFLD and cardiovascular disease. Dr. Long is primarily interested in patient-oriented research investigating fibrosis and inflammation in patients with NAFLD and in imaging and risk stratification strategies for hepatic fibrosis. Dr. Long has projects at Boston Medical Center and at the Framingham Heart Study where she is the PI of a study evaluating the prevalence and risk factors for liver fat (steatosis) and fibrosis. In Framingham, she is investigating the clinical and genetic correlates of hepatic steatosis and fibrosis as measured by transient elastography. Dr. Long receives research funding from the NIH (NIDDK), Doris Duke Charitable Foundation, Gilead Sciences, Echosens Corporation, and Boston University. She has expertise in epidemiology, visceral fat, liver imaging including computed tomography, ultrasound, and transient elastography. Dr. Long is also a clinical hepatologist and endoscopist.

Dr. Long is additionally interested in novel therapeutics for NAFLD and Non-alcoholic steatohepatitis (NASH) and runs the clinical trials program for the NAFLD Research Center.

Her other research interests include alcohol-related liver disease, hepatitis C, outcomes in end-stage liver disease/cirrhosis.

Education

Medicine-Internal, MD, Tufts University School of Medicine

Epidemiology, MSc, Boston University School of Public Health

Neuroscience/Neurology, BA, Middlebury College

Publications

Published on 4/5/2024

Alanaeme CJ, Ghazi L, Akinyelure OP, Wen Y, Christenson A, Poudel B, Dooley EE, Chen L, Hardy ST, Foti K, Bowling CB, Long MT, Colantonio LD, Muntner P. Trends in the prevalence of multiple chronic conditions among US adults with hypertension from 1999-2000 through 2017-2020. Am J Hypertens. 2024 Apr 05. PMID: 38576398.

Published on 1/5/2024

Fantasia KL, Austad K, Mohanty A, Long MT, Walkey A, Drainoni ML. Safety-Net Primary Care and Endocrinology Clinicians' Knowledge and Perspectives on Screening for Nonalcoholic Fatty Liver Disease: A Mixed-Methods Evaluation. Endocr Pract. 2024 Mar; 30(3):270-277. PMID: 38184239.

Published on 12/6/2023

Altajar S, Wang N, Rosenthaler MP, Murabito JM, Long MT. NAFLD Associates with Sarcopenia Defined by Muscle Mass and Slow Walking Speed: A Cross-Sectional Analysis from the Framingham Heart Study. J Clin Med. 2023 Dec 06; 12(24). PMID: 38137592.

Published on 11/17/2023

Dichtel LE, Corey KE, Haines MS, Chicote ML, Lee H, Kimball A, Colling C, Simon TG, Long MT, Husseini J, Bredella MA, Miller KK. Growth Hormone Administration Improves Nonalcoholic Fatty Liver Disease in Overweight/Obesity: A Randomized Trial. J Clin Endocrinol Metab. 2023 Nov 17; 108(12):e1542-e1550. PMID: 37379033.

Published on 11/17/2023

Donovan K, Thomas OW, Sweeney T, Ryan TJ, Kytomaa S, Zhao M, Zhong W, Long M, Rajendran I, Sarfaty S, Lenders C. Eat to Treat: The Methods and Assessments of a Culinary Medicine Seminar for Future Physicians and Practicing Clinicians. Nutrients. 2023 Nov 17; 15(22). PMID: 38004212.

Published on 9/1/2023

Stine JG, Long MT, Corey KE, Sallis RE, Allen AM, Armstrong MJ, Conroy DE, Cuthbertson DJ, Duarte-Rojo A, Hallsworth K, Hickman IJ, Kappus MR, Keating SE, Pugh CJA, Rotman Y, Simon TL, Vilar-Gomez E, Wong VW, Schmitz KH. Physical Activity and Nonalcoholic Fatty Liver Disease: A Roundtable Statement from the American College of Sports Medicine. Med Sci Sports Exerc. 2023 Sep 01; 55(9):1717-1726. PMID: 37126039.

Published on 8/28/2023

Weinstein G, O'Donnell A, Frenzel S, Xiao T, Yaqub A, Yilmaz P, de Knegt RJ, Maestre GE, Melo van Lent D, Long M, Gireud-Goss M, Ittermann T, Frost F, Bülow R, Vasan RS, Grabe HJ, Ikram MA, Beiser AS, Seshadri S. Nonalcoholic fatty liver disease, liver fibrosis, and structural brain imaging: The Cross-Cohort Collaboration. Eur J Neurol. 2024 Jan; 31(1):e16048. PMID: 37641505.

Published on 7/1/2023

Wong WJ, Emdin C, Bick AG, Zekavat SM, Niroula A, Pirruccello JP, Dichtel L, Griffin G, Uddin MM, Gibson CJ, Kovalcik V, Lin AE, McConkey ME, Vromman A, Sellar RS, Kim PG, Agrawal M, Weinstock J, Long MT, Yu B, Banerjee R, Nicholls RC, Dennis A, Kelly M, Loh PR, McCarroll S, Boerwinkle E, Vasan RS, Jaiswal S, Johnson AD, Chung RT, Corey K, Levy D, Ballantyne C, Ebert BL, Natarajan P. Author Correction: Clonal haematopoiesis and risk of chronic liver disease. Nature. 2023 Jul; 619(7970):E47. PMID: 37400552.

Published on 4/12/2023

Wong WJ, Emdin C, Bick AG, Zekavat SM, Niroula A, Pirruccello JP, Dichtel L, Griffin G, Uddin MM, Gibson CJ, Kovalcik V, Lin AE, McConkey ME, Vromman A, Sellar RS, Kim PG, Agrawal M, Weinstock J, Long MT, Yu B, Banerjee R, Nicholls RC, Dennis A, Kelly M, Loh PR, McCarroll S, Boerwinkle E, Vasan RS, Jaiswal S, Johnson AD, Chung RT, Corey K, Levy D, Ballantyne C, Ebert BL, Natarajan P. Clonal haematopoiesis and risk of chronic liver disease. Nature. 2023 Apr; 616(7958):747-754. PMID: 37046084.

Published on 4/4/2023

Gao V, Long MT, Singh SR, Kim Y, Zhang X, Rogers G, Jacques PF, Levy D, Ma J. A Healthy Diet is Associated with a Lower Risk of Hepatic Fibrosis. J Nutr. 2023 May; 153(5):1587-1596. PMID: 37023964.

View full list of 90 publications.